Lorazepam Intensol

drug-information.ru

|Lorazepam Intensol

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Lorazepam Intensol


Generic Name: lorazepam
Dosage Form: Oral concentrate usp 2 mg per ml

Rx only

Lorazepam Intensol Description

Each mL of IntensolTM contains:

Lorazepam ............................................ 2 mg

Lorazepam, an antianxiety agent has the chemical formula: 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one. The molecular weight is 321.2. The structural formula is:

Lorazepam is a white or practically white, practically odorless powder, insoluble in water, sparingly soluble in alcohol, slightly soluble in chloroform. Each mL of Lorazepam IntensolTM, to be taken orally, contains 2 mg of lorazepam.

Lorazepam Intensol - Clinical Pharmacology

Studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems.

Lorazepam is readily absorbed with an absolute bioavailability of 90 percent. Peak concentrations in plasma occur approximately one hour following administration. The peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/mL.

The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins. Lorazepam is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable CNS activity in animals.

The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to six months.

Studies comparing young and elderly subjects have shown that the pharmacokinetics of lorazepam remain unaltered with advancing age.

Indications and Usage for Lorazepam Intensol

Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.

Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Contraindications

Lorazepam is contraindicated in patients with known sensitivity to the benzodiazepines or with acute narrow-angle glaucoma.

Warnings

Lorazepam is not recommended for use in patients with a primary depressive disorder or psychosis. As with all patients on CNS-acting drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished.

Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (See DRUG ABUSE AND DEPENDENCE section).

Precautions

In patients with depression accompanying anxiety, a possibility for suicide should be borne in mind.

For elderly or debilitated patients, the initial daily dosage should not exceed 2 mg in order to avoid oversedation.

Lorazepam dosage should be terminated gradually, since abrupt withdrawal of any anti-anxiety agent may result in symptoms similar to those for which patients are being treated: anxiety, agitation, irritability, tension, insomnia, and occasional convulsions.

The usual precautions for treating patients with impaired renal or hepatic function should be observed.

In patients where gastrointestinal or cardiovascular disorders coexist with anxiety, it should be noted that lorazepam has not been shown to be of a significant benefit in treating the gastrointestinal or cardiovascular component.

Esophageal dilation occurred in rats treated with lorazepam for more than one year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6 times the maximum human therapeutic dose of 10 mg per day). The effect was reversible only when the treatment was withdrawn within two months of first observation of the phenomenon. The clinical significance of this is unknown. However, use of lorazepam for prolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper G.I. disease.

Information for Patients:

To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.

Essential Laboratory Tests:

Some patients on lorazepam have developed leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver-function tests are recommended for patients on long-term therapy.

Clinically Significant Drug Interactions:

The benzodiazepines, including lorazepam, produce CNS depressant effects when administered with such medications as barbiturates or alcohol.

Carcinogenesis and Mutagenesis:

No evidence of carcinogenic potential emerged in rats during an 18-month study with lorazepam. No studies regarding mutagenesis have been performed.

Pregnancy:

Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull and microphthalmia) were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses.

The clinical significance of the above findings is not known. However, an increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because the use of these drugs is rarely a matter of urgency, the use of lorazepam during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.

In humans, blood levels obtained from umbilical cord blood indicate placental transfer of lorazepam and lorazepam glucuronide.

Nursing Mothers:

It is not known whether oral lorazepam is excreted in human milk like the other benzodiazepine tranquilizers. As a general rule, nursing should not be undertaken while a patient is on a drug, since many drugs are excreted in human milk.

Pediatrics Use:

Safety and effectiveness of lorazepam in children of less than 12 years have not been established.

Adverse Reactions

Adverse Reactions, if they occur, are usually observed at the beginning of therapy and generally disappear on continued medication or upon decreasing the dose. In a sample of about 3500 anxious patients, the most frequent adverse reaction to lorazepam is sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). Less frequent adverse reactions are disorientation, depression, nausea, change in appetite, headache, sleep disturbance, agitation, dermatological symptoms, eye function disturbance, together with various gastrointestinal symptoms and autonomic manifestations. The incidence of sedation and unsteadiness increased with age.

Small decreases in blood pressure have been noted but are not clinically significant, probably being related to the relief of anxiety produced by lorazepam.

Transient amnesia or memory impairment has been reported in association with the use of benzodiazepines.

Drug Abuse and Dependence

Lorazepam IntensolTM [Oral Concentrate USP] is classified by the Drug Enforcement Administration as a schedule IV controlled substance.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (e.g., convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of lorazepam. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed.

Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving lorazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence.

Overdosage

In the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. Manifestations of lorazepam overdosage include somnolence, confusion, and coma. Induced vomiting and/or gastric lavage should be undertaken, followed by general supportive care, monitoring of vital signs, and close observation of the patient. Hypotension, though unlikely, usually may be controlled with norepinephrine bitartrate injection. The usefulness of dialysis has not been determined.

Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS and PRECAUTIONS should be consulted prior to use.

Lorazepam Intensol Dosage and Administration

Proper Use of an IntensolTM:

An Intensol is a concentrated oral solution as compared to standard oral liquid medications. It is recommended that an Intensol be mixed with liquid or semi-solid food such as water, juices, soda or soda-like beverages, applesauce and puddings.

Use only the calibrated dropper provided with this product. Draw into the dropper the amount prescribed for a single dose. Then squeeze the dropper contents into a liquid or semi-solid food. Stir the liquid or food gently for a few seconds. The Intensol formulation blends quickly and completely. The entire amount of the mixture, of drug and liquid or drug and food, should be consumed immediately. Do not store for future use.

Lorazepam is administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response.

The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day.

For anxiety, most patients require an initial dose of 2 to 3 mg/day given b.i.d. or t.i.d.

For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime.

For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated.

The dosage of lorazepam should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses.

How is Lorazepam Intensol Supplied

2 mg per mL IntensolTM Oral Concentrate USP

NDC 0054-3532-44: Bottles of 30 mL with calibrated dropper [graduations of 0.25 mL (0.5 mg), 0.5 mL (1 mg), 0.75 mL (1.5 mg) and 1 mL (2 mg) on the dropper].

PROTECT FROM LIGHT

Store at Cold Temperature–Refrigerate 2°-8°C (36°-46°F)

January 2003

4055805//02

© RLI, 2003


Lorazepam Intensol (Lorazepam)
PRODUCT INFO
Product Code 0054-3532 Dosage Form SOLUTION, CONCENTRATE
Route Of Administration ORAL DEA Schedule CIV
INGREDIENTS
Name (Active Moiety) Type Strength
lorazepam (lorazepam) Active 2 MILLIGRAM  In 1 MILLILITER
polyethylene glycol Inactive  
propylene glycol Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0054-3532-44 30 MILLILITER In 1 BOTTLE, DROPPER None

Revised: 08/2006





Where can I get more information about Lorazepam Intensol ? We recommend to use www.Drugs.com

Typical mistypes for Lorazepam Intensol
korazepam intensol, porazepam intensol, oorazepam intensol, lirazepam intensol, lkrazepam intensol, llrazepam intensol, lprazepam intensol, l0razepam intensol, l9razepam intensol, loeazepam intensol, lodazepam intensol, lofazepam intensol, lotazepam intensol, lo5azepam intensol, lo4azepam intensol, lorzzepam intensol, lorszepam intensol, lorwzepam intensol, lorqzepam intensol, loraxepam intensol, lorasepam intensol, loraaepam intensol, lorazwpam intensol, lorazspam intensol, lorazdpam intensol, lorazrpam intensol, loraz4pam intensol, loraz3pam intensol, lorazeoam intensol, lorazelam intensol, loraze-am intensol, loraze0am intensol, lorazepzm intensol, lorazepsm intensol, lorazepwm intensol, lorazepqm intensol, lorazepan intensol, lorazepak intensol, lorazepaj intensol, lorazepam untensol, lorazepam jntensol, lorazepam kntensol, lorazepam ontensol, lorazepam 9ntensol, lorazepam 8ntensol, lorazepam ibtensol, lorazepam imtensol, lorazepam ijtensol, lorazepam ihtensol, lorazepam inrensol, lorazepam infensol, lorazepam ingensol, lorazepam inyensol, lorazepam in6ensol, lorazepam in5ensol, lorazepam intwnsol, lorazepam intsnsol, lorazepam intdnsol, lorazepam intrnsol, lorazepam int4nsol, lorazepam int3nsol, lorazepam intebsol, lorazepam intemsol, lorazepam intejsol, lorazepam intehsol, lorazepam intenaol, lorazepam intenzol, lorazepam intenxol, lorazepam intendol, lorazepam inteneol, lorazepam intenwol, lorazepam intensil, lorazepam intenskl, lorazepam intensll, lorazepam intenspl, lorazepam intens0l, lorazepam intens9l, lorazepam intensok, lorazepam intensop, lorazepam intensoo, orazepam intensol, lrazepam intensol, loazepam intensol, lorzepam intensol, loraepam intensol, lorazpam intensol, lorazeam intensol, lorazepm intensol, lorazepa intensol, lorazepamintensol, lorazepam ntensol, lorazepam itensol, lorazepam inensol, lorazepam intnsol, lorazepam intesol, lorazepam intenol, lorazepam intensl, lorazepam intenso, olrazepam intensol, lroazepam intensol, loarzepam intensol, lorzaepam intensol, loraezpam intensol, lorazpeam intensol, lorazeapm intensol, lorazepma intensol, lorazepa mintensol, lorazepami ntensol, lorazepam nitensol, lorazepam itnensol, lorazepam inetnsol, lorazepam intnesol, lorazepam intesnol, lorazepam intenosl, lorazepam intenslo, llorazepam intensol, loorazepam intensol, lorrazepam intensol, loraazepam intensol, lorazzepam intensol, lorazeepam intensol, lorazeppam intensol, lorazepaam intensol, lorazepamm intensol, lorazepam intensol, lorazepam iintensol, lorazepam inntensol, lorazepam inttensol, lorazepam inteensol, lorazepam intennsol, lorazepam intenssol, lorazepam intensool, lorazepam intensoll, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved